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Summary
Background: The paternal allele of Ube3a is silenced by
imprinting in neurons, and Angelman syndrome (AS) is a disor-
der arising from a deletion or mutation of the maternal Ube3a
allele, which thereby eliminates Ube3a neuronal expression.
Sleep disorders such as short sleep duration and increased
sleep onset latency are very common in AS.
Results: We found a unique link between neuronal imprinting
of Ube3a and circadian rhythms in two mouse models of AS,
including enfeebled circadian activity behavior and slowed
molecular rhythms in ex vivo brain tissues. As a consequence
of compromised circadian behavior, metabolic homeostasis is
also disrupted in AS mice. Unsilencing the paternal Ube3a
allele restores functional circadian periodicity in neurons
deficient in maternal Ube3a but does not affect periodicity
in peripheral tissues that are not imprinted for uniparental
Ube3a expression. The ubiquitin ligase encoded by Ube3a
interacts with the central clock components BMAL1 and
BMAL2. Moreover, inactivation of Ube3a expression elevates
BMAL1 levels in brain regions that control circadian behavior
of AS-model mice, indicating an important role for Ube3a in
modulating BMAL1 turnover.
Conclusions: Ube3a expression constitutes a direct mecha-
nistic connection between symptoms of a human neurological
disorder and the central circadian clock mechanism. The
lengthened circadian period leads to delayed phase, which
could explain the short sleep duration and increased sleep
onset latency of AS subjects. Moreover, we report the phar-
macological rescue of an AS phenotype, in this case, altered
circadian period. These findings reveal potential treatments
for sleep disorders in AS patients.
Introduction
Angelman syndrome (AS) is a neurodevelopmental disorder of
imprinting characterized by mental disability, developmental
delays, sleep disorders, epileptic seizures, motor difficulties,
and speech impairment [1–3]. There is no specific therapy for
Angelman syndrome, and treatment for seizures usually be-
comes necessary. About 70% of AS patients have deletions
of the maternal copy of chromosome 15 in the region of
15q11-q13. The Ube3a gene within this region was identified
as the genetic locus for AS [4, 5], although neighboring genes
within the deleted region may contribute to the AS phenotype.
Ube3a encodes a HECT-domain E3 ubiquitin ligase (E6-AP)
that adds ubiquitin to substrates, thereby targeting them for*Correspondence: carl.h.johnson@vanderbilt.edudestruction in the proteasome [6]. AS is an example of
genomic imprinting that is caused by the deletion or inactiva-
tion of the maternal copy ofUbe3a, whereas the paternal copy
is imprinted and therefore silenced. Interestingly, the paternal
imprinting involved in AS occurs only in the brain [7–9] and is
imprinted neither in nonneural peripheral tissues [10, 11] nor
in glia [12, 13]. Normally (i.e., in non-AS subjects), the maternal
copy of Ube3a is active in neurons, whereas the paternal copy
is silenced in adult neurons. Therefore, inactivation or deletion
of the maternal copy causes a gene dosage effect whereby
there is a significant loss of total E6-AP activity in neurons,
resulting in AS.
Sleep disorders such as short sleep duration and increased
sleep onset latency are very common in AS patients (up to 75%
of subjects suffer from sleep disturbances [14, 15], and these
sleep disruptions are one of the syndrome’s most stressful
manifestations to families with an AS member [16]. Almost all
of the information about sleep disruptions in AS patients are
clinical/behavioral observations, with the exception of a study
of daily profiles of the hormonemelatonin that concluded there
was a high prevalence of circadian rhythm sleep disorders
among AS patients [17]. The timing of sleep is regulated by
the circadian clock, and, in a Drosophila model for AS based
on a null mutation of the fly counterpart to Ube3a (dube3a),
circadian rhythmicity and activity/rest cycles are abnormal
[18]. Moreover, two other imprinted genes, Gnas and Magel2,
have consequences for sleep architecture and circadian
amplitude inmice [19, 20], and the paternally imprintedMagel2
is located within the commonly deleted 15q11-q13 Angelman/
PWS interval. A recent publication reported that a clock pro-
tein that is a central component of the mammalian circadian
clock, BMAL1 (ARNTL in humans), is an ubiquitinylation target
of E6-AP [21]. Despite these tantalizing connections between
AS, sleep disruptions, and circadian rhythmicity, there have
been no reports of the consequences of reduced Ube3a
dosage in mammals in vivo that confirm an effect on circadian
period, phase, and metabolism.
On the other hand, the general significance of ubiquitin-
mediated turnover of circadian clock proteins in the mecha-
nism of circadian rhythmicity has been appreciated since the
first observations in model systems Drosophila and Neuros-
pora [22, 23]. Recent mammalian studies using mouse strains
with mutated/knocked-out genes to the F-box proteins Fbxl3
and Fbxl21 that participate in SCF-mediated ubiquitinylation
of the central clock protein CRYPTOCHROME (CRY) [24–28]
demonstrate the principle that alterations of clock protein
ubiquitinylation can cause circadian phenotypes, but those
investigations of SCF/Fbxl have not been linked to any defects
or syndromes in humans. Moreover, the E3 ligase encoded
by Ube3a (E6-AP) is a single protein that associates with an
E2 ubiquitin conjugating enzyme and the target substrate,
whereas the SCF ubiquitin ligases are multimeric complexes
[6]. This difference in the ubiquitinylation reaction between
E6-AP and SCF complexes could have distinct mechanistic
consequences.
We report here that mouse models of AS display altered
circadian period and phase, and these phenotypes can be
further exacerbated by manipulating the environmental light/
dark conditions. Re-entrainment kinetics of the circadian
Figure 1. Maternal Deletion of Ube3a or the Ube3a-Gabrb3 Region Alters Circadian Behavior and Entrainment in Mice
(A) Representative wheel-running activity records (actograms) of mice are shown in the double-plotted format. Mice (4-month-old littermates) were
wild-type (WT, left) ormaternal deletion (U-m-/p+,middle) and paternal deletion (U-m+/p2, right) ofUbe3a. Micewere initially in a 12-hr-light/12-hr-dark cycle
(blue indicates light, white indicates dark) and were then transferred to constant darkness (DD) on day 8.
(B) The free-running period of wheel-running behavior in the mice depicted in (A) (n = 5 or 6). Mean 6 SEM, *p < 0.05 compared with WT, one-way ANOVA,
post hoc Tukey test.
(C) Representative examples of double plotted actograms of total activity inWT (left) versus maternal deletion of theUbe3a-Gabrb3 region (UG-m-/p+, right)
mice measured by infrared sensors (mice were 4-month-old littermates).
(D) The free-running period of total activity in the mice depicted in (C) (n = 3 or 4). Mean 6 SEM, **p < 0.01, two-tailed t test.
(E–H) WT and U-m-/p+ mice were entrained to a 12-hr/12-hr light-dark (LD 12/12) cycle for at least 10 days and then subjected to a 6 hr advance of the LD
cycle for at least 10 days, followed by 6 hr delay of LD. As shown by representative actogram records of wheel-running locomotor activity (E) or statistical
analyses of activity onset (F–H) U-m-/p+ mice re-entrained to the phase-advanced LD significantly faster than did WT mice (n = 6 per genotype). (F) Mean6
SEM p < 0.001 for the genotype factor, namely, WT versus U-m/p+ (two-way ANOVA). (G and H) Two-tailed t test, **p < 0.01 in (G).
See also Figures S1 and S2.
538system to shifted light/dark cycles are also altered in the AS-
model mice. In addition to the change of circadian properties
that is induced by the environmental conditions, there is a
concomitant change in metabolism such that the AS mice
gain excess body fat, which is consistent with the growing
literature on the connection between circadian clocks and
metabolism [29–34].Moreover, we found that pharmacological
reactivation of paternal Ube3a in AS brain slices restores
circadian periodicity in E6-AP-deficient neurons. We conclude
that deficiency of neuronal E6-AP activity (as in AS) leads
to defective ubiquitinylation of clock proteins that alters
circadian-clock-mediated behavior and metabolism. The
data are consistent with a conclusion that altered circadian
properties in AS subjects underlie the sleep disorders that
characterize AS.
Results
We tested the circadian phenotypes of two different mouse
models that are based on the most common genetic defect
found in AS, namely, anw4 Mb deletion in the maternal copy
of chromosome 15 (region 15q11-q13, which includes the
Ube3a locus) that leads to reduced E6-AP expression in pater-
nally imprinted brain regions [4, 5]. As shown in Figure S1,
there is excellent synteny between this region of human chro-
mosome 15 and region 7p of mouse chromosome 7 [35]. One
of these mouse models carries a 299 bp deletion within the
Ube3a gene on the maternal chromosome 7 that confersa null mutation (herein called U-m-/p+) [8]. U-m-/p+-model
mice exhibit phenotypes that are similar to those of AS
patients, including motor dysfunction, locomotor problems,
inducible seizures, context-dependent learning deficits, sleep
disturbances, and changes in CaMKII phosphorylation pat-
terns that cause hippocampal long-term potentiation (LTP)
deficits [8, 9, 36, 37]. The second mouse model is a 1.6 Mb
deletion from Ube3a to Gabrb3 on maternal chromosome 7,
which removes the syntenous Ube3a, Atp10a, and Gabrb3
loci (herein called UG-m-/p+; Figure S1) [38]. UG-m-/p+ mice
show increased spontaneous seizure activity and abnormal
EEG, with concomitant significant impairment in motor func-
tion, learning/memory tasks, and anxiety-related measures;
the researchers who generated the UG-m-/p+ mice concluded
that it is an even more accurate model of AS than the U-m-/p+
mice with a maternal deletion only within Ube3a [38].
Deficiency of E6-AP Expression in the Brain Alters
Circadian Behavior
The free-running circadian rhythm of locomotor activity
behavior is significantly prolonged in both the U-m-/p+ and
UG-m-/p+ mice (Figure 1). In U-m-/p+ mice, the rhythm of
wheel-running behavior in constant darkness (DD) is 0.3 hr
longer than that of wild-type (WT) mice (p < 0.05), whereas
deletion of the paternal copy ofUbe3a (U-m+/p2) has no signif-
icant effect on this circadian rhythm (Figures 1A and 1B). The
impact upon the circadian rhythm was more profound in the
larger deletion UG-m-/p+ mice and resulted in a 0.6 hr slowing
Figure 2. Environmental Exposure to Constant Light Differentially Sup-
presses the Amplitude of Circadian Locomotor Rhythms and Prolongs
Subsequent Period when Ube3a Is Deficient in the CNS
(A) Representative wheel-running actograms of WT and U-m-/p+ mice
(7 months old) exposed to LL for 4 weeks and then returned to DD for
4 weeks. (Blue, light; white, dark.)
(B–D) Amplitude (B), period (C), and magnitude (D) of wheel-running activity
before (DD Pre LL), during (LL), and after (DD Post LL) exposure to LL. The
bar are depicted asmean6 SEM, n = 5 or 6, *p < 0.05, **p < 0.01, ***p < 0.001
compared with the corresponding WT group (two-tailed t test).
539of the period of total activity (p < 0.01, Figures 1C and 1D) and
of wheel-running activity (Figure S2). Not only was the timing of
wheel-running activity affected in the AS-model mice (Figures
1A and 1B), total activity was also reduced. Another critical
circadian behavior that is affected in the AS-model mice is
the kinetics of re-entrainment after a phase-shift of the light/
dark (LD) cycle (Figures 1E–1H). WT mice require 4 or more
days to re-entrain to a 6 hr advance in the phase of the LD cy-
cle, but the U-m-/p+ mice re-entrain to the shifted LD cycle
significantly faster, within 2 days or less (p < 0.01, Figure 1G).
On the other hand, both WT and U-m-/p+ mice re-entrain
rapidly to delayed LD cycles (Figure 1H). These data on period
and re-entrainment kinetics denote a weakening of the central
circadian oscillator strength in AS-model mice.
Environmental exposure to constant light (LL), which is
known to disrupt and/or suppress circadian activity patterns,
has a significantly stronger effect on U-m-/p+ mice as
compared with WT mice (Figure 2). During the exposure to
LL, activity levels and rhythm amplitude are suppressed in
WT mice, but they are practically nonexistent in U-m-/p+
mice (Figures 2A, 2B, and 2D). Moreover, after returning to
DD, WT mice recover their activity levels and rhythm ampli-
tude, but U-m-/p+ mice do not fully recover. The impact of
LL on circadian period is even more interesting. As is well
known, LL lengthens the period of WT mice, but we observed
that LL-induced slowing of U-m-/p+mouse periodicity is larger
(Figure 2C; the enhanced variability is due to the suppression
of activity that complicates accurate period estimation).
Most fascinating is the difference in circadian period after re-
turn to DD; WT mice recover their period to the pre-LL value,
but U-m-/p+ mice experience an ‘‘after’’-effect on their period
that persists. Before exposure to LL, the difference between
WT and U-m-/p+ periods is significant at the p < 0.05 level(Figures 1B and 2C), but, after LL exposure, the difference
is now significant at the p < 0.01 level (Figure 2C). The obser-
vation that LL suppression of circadian rhythmicity is more
deleterious to amplitude and period in U-m-/p+ mice further
supports the conclusion that normal levels of E6-AP expres-
sion enhance circadian oscillator strength.
Ube3a Gene Dosage Effects Are Brain Specific and Can Be
Rescued by Topotecan
Mammalian circadian systems are composed of oscillators in
tissues throughout the organism that are coordinated by a
central pacemaker in the suprachiasmatic nuclei (SCN) of the
hypothalamus [39]. When oscillations are assessed with a
luciferase reporter of gene/protein expression, both the SCN
and the nonneural peripheral tissues exhibit robust circadian
rhythms in vitro [40, 41]. We introduced the PmPer2::mPER2-
LUC reporter of expression of the central PER2 clock protein
[41] into WT, U-m-/p+, and UG-m-/p+ mice. SCN tissues
in vitro retain the period difference between WT and U-m-/p+
strains (Figures 3A and 3B), and these molecular rhythms
also damp more rapidly in U-m-/p+ SCN slices (Figure 3C). In
contrast, neither the U-m-/p+ or UG-m-/p+ peripheral tissue
(spleen and lung) show period differences from WT (Figures
3D and 3E). This result implies that the expression of E6-AP
from the active paternal allele of Ube3a in peripheral tissue
of AS-model mice is sufficient to promote wild-type clock
function, but, in the brain tissue (SCN) where the paternal allele
is inactivated, E6-AP activity is reduced to the degree that
clock properties are impaired.
However, the paternal Ube3a allele can be unsilenced.
An exciting new development in the potential treatment of
AS is the use of the topoisomerase inhibitor topotecan to
reactivate the dormant paternal Ube3a allele in neurons [42].
We observed that nanomolar concentrations of topotecan
restored the long period of the PER2 expression rhythm in U-
m-/p+ SCN slices to a WT value (Figures 3A and 3B), as well
as preventing the accelerated damping (Figure 3C). Topotecan
does not have significant effects on the period of peripheral
lung tissue where the Ube3a paternal allele is still active (Fig-
ure 3E). There is an intriguing trend toward topotecan short-
ening the period expressed by WT SCN, but this difference is
not statistically significant (Figure 3B). However, because
there is one active Ube3a allele in WT SCN (maternal) and
two active Ube3a alleles in WT lung, the trend toward topote-
can-induced shortening the period of WT SCN (Figure 3B)
without affecting the period of WT lung (Figure 3E) implies
that topotecan effects on period are not due to a nonspecific
side effect (if this were true, the period in the lung should
also be affected) but are attributable to the reactivation of
the paternal Ube3a allele in WT SCN, thereby increasing E6-
AP activity and speeding the clock.
Reciprocal Regulatory Network between Ube3a and the
Central Clock Gene Bmal1
Key components of the autoregulatory transcriptional feed-
back mechanism of the mammalian circadian clock are the
heterodimeric activators BMAL1/CLOCK and BMAL1/NPAS2
that act as positive elements to drive transcription on E-box
motifs in many target genes including Per1, Per2, and Avp
[43–45]. The upstream region of Ube3a comprises several E-
boxes and is therefore predicted to be regulated by BMAL1
in association with CLOCK and/or NPAS2. E-box-containing
genes are often—but not always—regulated rhythmically
[46]. The latter case appears to apply to Ube3a. In liver,
Figure 3. Ube3a Gene Dosage Effects Are Brain
Specific and Rescued by Topotecan
(A) Maternal deletion of Ube3a alters molecular
rhythms in explanted suprachiasmatic nuclei
(SCN), as assessed with a luminescence reporter
of mPER2 expression. SCN slices were collected
from PmPer2::mPER2-LUC knockin mice in the
WT and U-m-/p+ backgrounds. Tissue explants
were dissected on day 0 and recorded with a
LumiCycle apparatus. Blue, WT; red, Ube3a
m-/p+; black, WT SCN plus topotecan; green:
Ube3a m-/p+ plus topotecan (300 nM topotecan
added to the medium at the beginning of culture).
(B and C) Period (B) and damping rate (C) ana-
lyses of SCN data (representative examples
shown in A) plotted as mean 6 SEM (n = 5–7
SCN slices from five to seven animals), *p <
0.05, **p < 0.01 compared with WT or as indi-
cated, one-way ANOVA, post hoc Tukey test.
(D and E) Neither maternal deletion of Ube3a nor
topotecan alters PER2 molecular rhythms in
explanted peripheral tissues. (D) Period of PmPer2::mPER2-LUC luminescence rhythms from spleen tissue in vitro from WT, U-m-/p
+, and UG-m-/p+
mice. (E) Period of PmPer2::mPER2-LUC luminescence rhythms from lung tissue derived from WT, U-m-/p
+, and UG-m-/p+ mice plus and minus topotecan.
At least seven animals were used in each group (mean 6 SEM; 300 nM topotecan was added to the lung tissues when culturing began).
540Ube3a transcript levels are not rhythmic in DD in the same
samples in which Per2mRNA rhythmicity was confirmed (Fig-
ure 4A). Immunoblot analyses of E6-AP levels at two circadian
phases showed no difference in protein levels in WT hypothal-
amus, while confirming the tremendous reduction of E6-AP
levels in U-m-/p+ brain tissue (Figure 4B). Consistent with the
presence of several potential E-boxes in the 2.1 kb upstream
region of Ube3a, a PUbe3a::Luc reporter was galvanized by
both BMAL1/CLOCK and BMAL1/NPAS2 coactivators (Fig-
ure 4D). However, this PUbe3a::Luc reporter is not regulated
rhythmically under the same conditions that PPer2 and PBmal1
activity is rhythmic (Figures S3A and S3B), which is consistent
with the lack of a rhythm in transcript or protein abundance
(Figures 4A and 4B). In addition, E6-AP does not directly acti-
vate the expression of other E-box-containing promoters,
such as PPer1 or PAvp (Figures S3C and S3D). Despite not being
rhythmically regulated, however, Ube3a expression is at the
behest of BMAL1. In liver of Bmal12/2 knockout mice, the level
of Ube3a mRNA expression is one-third of its level in WT liver
(Figure 4C).
Although Ube3a expression is controlled by BMAL1, E6-AP
reciprocally regulates BMAL1 activity by modulating BMAL1
stability. BMAL1 has been recently identified as an in vitro
target of E6-AP-catalyzed ubiquitinylation [21]. Consistent
with those observations, we confirm in vivo that the BMAL1
protein abundance is significantly higher in the hypothala-
mus of U-m-/p+ mice at two opposite circadian phases, as
expected if E6-AP ubiquitinylates and destabilizes BMAL1
(Figure 5A; two-way ANOVA for WT versus U-m-/p+, p <
0.0013). E6-AP physically interacts with BMAL1 and its
paralog BMAL2 [47], as indicated by coimmunoprecipitation
of E6-AP with BMAL1/BMAL2 from extracts of these proteins
expressed in HEK293 cells (Figure 5B). This interaction was
not observed between E6-AP and PER1/2 or CRY1/2 (Fig-
ure S4). Although E6-AP expression does not affect E-box-
mediated transcription directly (Figures S3C and S3D), it
does reduce BMAL1/CLOCK transactivation of E-box activity
(Figure 5C). This E6-AP-mediated reduction in BMAL1/
CLOCK activity is likely to be due to ubiquitinylation/destabi-
lization of BMAL1, because Ube3a expression does not
directly affect the activity of the Bmal1 promoter (unlike thetranscriptional factor Rev-Erb-a, which is known to repress
PBmal1 [48], Figure 5D).
Body Weight and Activity Patterns Are Altered in
AS-Model Mice
A blossoming literature underscores the intimate connec-
tion between circadian clocks and metabolism, including
the observation that disruptions of the circadian system
lead to metabolic dysfunctions [29–34]. In addition to sleep
disorders, human syndromes that result from maternal and
paternal deletions on chromosome 15 (AS and Prader-Willi
syndrome [PWS]) have associated metabolic phenotypes
including altered activity levels and weight gain/loss problems
(AS [49], PWS [50, 51]). We found similar phenotypes in the
AS-model mice that have altered circadian properties. With
the maternal deletion in Ube3a alone (U-m-/p+), body weight
is significantly higher than in WT mice, and this difference is
mostly attributable to an increase of fat mass (Figures 6A–
6C). These animals were fed regular chow, so feeding a
high-fat diet is not necessary to promote these differences
in weight gain. Moreover, the heavier weight of U-m-/p+
mice is not due to an increased food intake (Figure 6E).
On the other hand, the wheel-running activity of U-m-/p+
mice is less than that of WT mice (Figures 2D and 6D), and
the energy balance might therefore tip toward greater weight
gain in the U-m-/p+ mice.
Similarly, the other AS-model mouse strain in which the
entire Ube3a-Gabrb3 region is deleted from the maternal
chromosome (UG-m-/p+) exhibits increased weight gain and
altered daily activity patterns. UG-m-/p+ mice are significantly
heavier thanWT at an age of 10months, even when fed regular
chow (Figure S5A). This difference may be related to a lower
overall activity level, because UG-m-/p+ mice have less total
activity than WTmice in LD (Figure S5B). An interesting obser-
vation of the activity pattern of UG-m-/p+ mice in LD is that the
major activity bout is distributed toward the end of the dark
interval, whereas in WT mice the activity predominates in the
early portion of the dark interval of LD (Figures 6F, S5C, and
S5D). This patterning can be seen visually in the raw data of
Figure 1C. The phenomenon is consistent with the interpreta-
tion that the longer circadian period in DD of the AS-model
Figure 4. Ube3a Expression Is Dependent upon
the Clock Factors BMAL1, CLOCK, and NPAS2
but Is Not Rhythmically Expressed
(A) Transcript levels for Ube3a (left) and Per2
(right) in liver. Ube3a and Per2 mRNA levels
were quantified by real-time PCR and normalized
with reference to Hprt mRNA levels. The data
were normalized by setting the value to 1.0
for the mRNA levels at hour 44 in DD (=CT8).
n = 4–7 mice.
(B) Upper panel: E6-AP and b-ACTIN protein
levels in mouse hypothalamus (WT and U-m-/p+
mice) from two different circadian phases in DD
(hour 26, which is CT14 in the early subjective
night, and hour 38, which is CT2 in the early sub-
jective day). Data are immunoblots of hypothala-
mus extracts from four separate mice (each
lane is the extract from a separate mouse). The
difference between the upper and middle panels
of immunoblots (E6-AP) is the exposure duration.
Lower panel: densitometric analyses of the data
in the upper panel. The E6-AP expression of
U-m-/p+ at DD 38 hr is set as 1. Statistics: p <
0.0001 for genotype factor (WT versus U-m-/p+)
by two-way ANOVA.
(C) Levels ofUbe3a transcript expression inWT (left) versusBmal12/2 (right) liver in subjective night (at DD, 50–56 hr; for WT, this time equals CT 14–20). The
mRNA was quantified by real-time PCR and normalized to HprtmRNA controls. The value of WT mRNA levels was set as 1.0. At least six mice were used in
each group. **p < 0.01, two-tailed t test.
(D) BMAL1/CLOCK (B1/CLOCK) and BMAL1/NPAS2 (B1/NPAS2) transactivation of the mUbe3a upstream region as assessed by a transient transfection
assay in HEK293 cells. Data are mean6 SEM (n = 4) using a PUbe3a::Luc firefly luciferase reporter driven by 2.2 kb of the mUbe3a upstream region including
220 bp of the 50 UTR, and normalized by aRenilla luciferase control (PCMV::Rluc). ***p < 0.001 compared with empty vectors control (Con), which is set as 1.0,
one-way ANOVA, post hoc Tukey test.
See also Figure S3.
541mice manifests as a later phase of activity under LD as pre-
dicted by entrainment theory [52, 53].
Modulating Ube3a Expression in Cell Cultures Alters
Circadian Properties
Stifling Ube3a expression lengthens the circadian period,
whether this suppression is by maternal deletion in neurons
(intact animal behavior, Figures 1 and 2; SCN brain slices,
Figure 3) or by small interfering RNA knockdown in fibroblast
cell cultures [21]. The converse manipulation—increasing the
level of Ube3a expression—has the predictably opposite
result. When transfected with a plasmid that overexpresses
Ube3a, the rhythm of both mouse embryonic fibroblasts and
Rat-1 fibroblasts exhibits a shorter period at low concentra-
tions (Figures S6A, S6B, and S6D), and then suppression and
disruption of the rhythm at higher concentrations (Figures
S6C and S6D).
Discussion
Neuronal Imprinting of Paternal Ube3a Modulates
Circadian Properties
Our results show that tissue-specific differences in the expres-
sion levels ofUbe3a have a large effect on circadian properties
because the encoded ligase E6-AP modulates the stability of
the core clock protein BMAL1. Gene dosage effects of Ube3a
are associated with Angelman syndrome and autism [4, 5, 7–
13, 54]; therefore, some key phenotypes of these disorders
may be attributable to E6-AP-dependent effects upon the
circadian system. The current model for the molecular mecha-
nism of the mammalian circadian clockwork proposes auto-
regulatory transcriptional and translational feedback loops
(TTFLs) of central clock gene expression [55–57]. There is an
ensemble of different molecular components that are believedto participate in a feedback loop of clock proteins that are
rhythmically abundant and interactwitheachother tomodulate
their activities. Rhythmic transcriptional ‘‘drive’’ is provided
by thepositivebHLH-PAS transcription factor,BMAL1/ARNTL,
which dimerizeswith CLOCKorNPAS2 [44, 45]. TheseBMAL1/
CLOCK and BMAL1/NPAS2 heterodimers activate transcrip-
tion primarily at E-box enhancers [43]. Negative feedback
in the system is primarily accomplished by Per and Cry gene
products.
The TTFL model posits that rhythmic abundance of at least
one central clock protein is necessary to accomplish the rhyth-
mic negative feedback, which implies that turnover is a crucial
parameter of the clockwork. Indeed, the abundance of the
PER and CRY negative-feedback proteins are rhythmic [58,
59]. Recent investigations have analyzed the role of SCF-medi-
ated ubiquitinylation in regulating CRY protein turnover by the
F-box proteins Fbxl3 and Fbxl21, which, in turn, modulates
circadian period [24–28]. However, cycling of the positive fac-
tor BMAL1 has been thought to be unnecessary for basic clock
function [60]. Nevertheless, the period lengthening observed in
U-m-/p+ andUG-m-/p+mice (Figures 1, 2, and 3) is reminiscent
of the results obtained with mutations in F-box proteins that
participate in rhythmic turnover of CRY [24–28]. Moreover,
in vitro studies confirm that manipulating BMAL1 stability
by changing E6-AP expression/activity has significant impact
upon circadian period and amplitude (Figures 3 and S6 and
[21]). Apparently, when E6-AP activity is low (as when Ube3a
gene dosage is reduced in the AS-model mice), BMAL1 is sta-
bilized (Figure 5A and [21]) and the circadian oscillator is less
robust. This weakening ismanifested as a longer period in vivo
and in vitro, enhanced damping in vitro, reduced in vivo
amplitude in LL, prolonged LL-induced period after effects,
and more rapid re-entrainment to a phase-advanced LD cycle.
Our results are also consistent with other studies in which
Figure 5. The Stability of BMAL1 Is Regulated by
Ube3a Expression In Vivo
(A) Left panel: immunoblots of BMAL1 in hypo-
thalamus of U-m-/p+ and WT mice placed in DD
for 26 and 38 hr (CT14 and CT2, respectively).
b-actin serves as the loading control (each lane
comes from a separate mouse; one representa-
tive immunoblot is shown). Right panel: densito-
metric analyses of the BMAL1 expression for
two independent experiments (E1 and E2; an
immunoblot for E2 is shown in the left panel).
BMAL1 expression of WT at DD 26 hr is set as 1
(‘‘B12/2’’ = Bmal12/2; ‘‘MW’’ = a protein band of
molecular weight 75 kDa). Two-way ANOVA sta-
tistical analyses show significant differences for
both genotype (WT versus U-m-/p+, p = 0.0013)
and for time (DD 26 hr versus DD 38 hr,
p = 0.0029).
(B) Interaction between BMAL1 (B1) or BMAL2
(B2) and E6-AP in HEK293 cells transfected with
Myc-mBmal1/2 and HA-hUbe3a. Immunoprecip-
itates were prepared using an anti-HA antibody
and the immunoprecipitates (IP) and original cell
lysates (IB) were separated by electrophoresis and immunoblotted with either anti-HA (for E6-AP) or anti-Myc (for BMAL1 or BMAL2) (M, mock control,
pCDNA3.1 vector).
(C) Ube3a expression reduces BMAL1/CLOCK activation of E-box reporter PPK2.8::Luc in HEK293 cells. Data (mean 6 SEM, n = 4) were normalized to the
PCMV::Rluc control and expressed relative to empty vector controls. ***p < 0.01, one-way ANOVA, post hoc Tukey test.
(D)Ube3a expression does not affect the promoter activity ofBmal1. Data are mean6 SEM (n = 4) of firefly luciferase activity (PBmal1-Fluc) normalized to the
PCMV::Rluc control. **p < 0.01 compared with empty vectors control (Con), which was set to a value of 1.0, one-way ANOVA, post hoc Tukey test.
See also Figures S4 and S6.
542enhanced expression of BMAL1 in cell cultures causes a
lengthening of circadian period [61].
It is counterintuitive that enhancing the abundance/stability
of the positive transcriptional factor BMAL1 will lead to a less
robust circadian pacemaker. However, two recent reports
have shown that metabolic inputs to the clock, including
entrainment by restricted feeding paradigms, are mediated
by adjusting the stability of BMAL1 [62, 63]. Taken together,
these results underscore that much remains to be learned
about the mechanism of the mammalian circadian clockwork,
including that inputs to the clockmay bemediated through the
positive element BMAL1, and not only through the negative-
feedback elements PER and CRY. Finally, a fascinating aspect
about circadian organization within the AS-model mice is that
the paternal Ube3a allele is inactivated only in neurons. There-
fore, U-m-/p+ and UG-m-/p+ mice become a genetic mosaic
as regards Ube3a expression and, by extension, a circadian
mosaic. Our data support this interpretation in the AS-model
mice; as shown in Figure 3, the circadian period and amplitude
effects are observed in SCN slices (neural tissue where the
paternal Ube3a allele is silenced), but not in lung or spleen
(non-neural peripheral tissue where the paternal Ube3a allele
is active).
Ube3a-Dependent Circadian Modulation Generates
Phenotypes Associated with AS and PWS
Common forms of the human syndromes Angelman syndrome
(AS) and Prader-Willi syndrome (PWS) are associated with
imprinting/inactivation of Ube3a on one chromosome and
deletion on the other chromosome. Sleep disorders that can
lead to behavioral issues are associated with both AS and
PWS, especially in childhood [16]. In the case of AS, the sleep
problems include increased sleep onset latency and reduced
total sleep duration [3, 15–17]. Sleep disruption can also occur
in AS subjects because of seizures, but, even in AS subjects
with no or minimal seizures, the sleep latency/durationsymptoms persist. The longer periods of the U-m-/p+ and
UG-m-/p+ mice can provide an explanation for these pheno-
types in humans. In particular, from entrainment theory, longer
circadian periods can manifest as a later phase relationship of
rhythm to the light/dark cycle [52]. This happens because the
longer period requires a larger advance phase shift in order
to entrain to a 24 hr LD cycle, and this is accomplished by illu-
minating a different portion of the phase-shifting landscape
known as the phase response curve. A later phase relationship
between the activity/sleep cycle and the LD cycle will allow a
longer endogenouscircadianperiod toentrain to the 24hr envi-
ronmental cycle [52], and even a small change in period can
bring about a large change in the phase relationship [53]. Fig-
ures 1C, 1D, and 6F indicate that the nocturnal activity of AS-
model mice is distributed into a later phase relationship in LD
cycles, and this altered phase relationship could disturb sleep
in theAS-modelmice [37]. In humans, a later phase relationship
leads to delayed sleep phase syndrome (DSPS) in which sub-
jects go to sleep later (i.e., increased sleep onset latency) and
wake up later in the morning. Several studies confirm that
DSPS in humans is associated with a longer period of the mo-
lecular clock [64–67]. AS children have increased sleep onset
latency [15], and if their parents rouse them at the usual
wake-up time, then they will also experience a reduced total
sleep duration [15]. The application of non-invasive chrono-
therapeutic strategies designed for persons suffering from
affective disorders [68] may enhance the entrainment of AS
subjects and improve the quality of their sleep.
Metabolism and circadian rhythmicity havemutual feedback
upon each other [29–34]. We observed another example of
these complementary relationships in the AS-model mice.
Both the U-m-/p+ and the UG-m-/p+ mice gained more weight
thanWT littermates under the same conditions, and this effect
may be related to either a slightly lower level of overall activity
(Figures 6 and S5), and/or the suppression of rhythmicity as
we concluded in a previous study [34]. AS-model mice are
Figure 6. Maternal Deletion of Ube3a Impairs
Metabolic Homeostasis in Mice
U-m+/p+ (WT) and U-m-/p+ mice were fed regular
chow, and their body composition, locomotor ac-
tivity, and food consumption were measured.
(A) Body weight (n = 5–6/genotype).
(B and C) Body composition was measured by
nuclear magnetic resonance as lean mass (B)
and fat mass (C) at age 4 months (in LD) and
8 months (sequentially in LD, DD, and LL over
the 8 months) (n = 5–6/genotype).
(D) Wheel-running locomotor activity recorded at
different ages and under various light/dark condi-
tions (n = 5–6/genotype).
(E) Average daily food intake over 24 hr in LD
versus LL (n = 5–6/genotype). Each bar repre-
sents mean 6 SEM; *p < 0.05, **p < 0.01, ***p <
0.001 compared with the corresponding WT
group, two-tailed t test.
(F) Relative daily activity patterns in LD of WT
(blue) versus UG-m-/p+ (red) mice. Total loco-
motor activity was recorded with infrared sen-
sors from mice in LD. ZT0 denotes lights-on,
and ZT12 denotes lights-off. The lines connect the mean values over 7 days in LD of the 1 hr moving averages. The data are normalized as the
highest unnormalized activity level (see Figure S5C) of each individual mouse during 24 hr adjusted to 1 (nR 3).
See also Figure S5.
543consistently overweight [36], and metabolic phenotypes are
also associated in humans with altered expression of Ube3a.
For example, whereas AS subjects with chromosomal dele-
tions are rarely overweight, those with uniparental disomy or
imprinting center mutations are commonly overweight [69].
In addition, whereas obesity is a hallmark feature of its sister
imprinting syndrome, PWS, mouse models of PWS are rarely
overweight [70]. These correlations suggest that the ASmouse
models may have rhythmic similarities to AS, but metabolic
similarities to PWS [70]. Therefore, neuronal inactivation of
paternalUbe3a in mice whosematernalUbe3a gene is deleted
recapitulates sleep and metabolic symptoms of human syn-
dromes that are associated with imprinting of chromosomal
region 15q11-q13 (AS and PWS). It will be fascinating to
test whether overexpression of maternal Ube3a, such as in
uniparental disomy or imprinting center mutation genotypes
of PWS, reciprocally affects circadian period and metabolic
status.
By virtue of its regulation of the stability of the core clock
component BMAL1, E6-AP acts as a key modulator of the
circadian system, thereby affecting fundamental properties
such as period, amplitude, and entrainment kinetics. New
pharmaceutical treatments to unsilence paternal Ube3a are
currently under development [42, 49] that may treat or amelio-
rate the disorder at its genetic root. The circadian abnormal-
ities identified in this study may serve as a biomarker for
clinical trials of these medications in their early phases. More-
over, translational applications may result from the elucidation
of the connections between Ube3a expression and circadian
rhythms, because this research could lead to therapies
of non-invasive alterations of environmental conditions to
ameliorate at least some of the symptoms of AS. Such transla-
tional applications are suggested by the exacerbation of
period and metabolic phenotypes by a clock-perturbing envi-
ronmental parameter, namely LL (Figure 2). If environmental
conditions that interact with the circadian system can exacer-
bate undesirable phenotypes (such as LL), it is likely that envi-
ronmental conditions can be identified that have an opposite
impact upon circadian properties such that symptoms can
be improved [68].Experimental Procedures
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